View

The Study

Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study

In simple terms

This study gave people with a type of eye disease a special vitamin pill and found that after a year, their eyes showed some improvement in a lab test. But it didn't prove the pill stops their vision from getting worse in the long run — just that it helped a little in the short term.

71%

Analysis score

71/ 90

Maximum 90 for a randomized controlled trial.

Where the score came from

Reporting40
Methodology89
Publication100
Statistical46
Study type (basis of the score)
Randomized Controlled Trial
Level 1b - Individual RCT
What’s the bottom line?

This study tested if taking a daily pill with special eye vitamins helps slow down vision loss in older people with early-stage macular degeneration.

Where does this study sit?

Reviews of RCTs (Meta-analyses)

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Randomized Trials
Level 1b
71

71 / 100

Quality score

Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.

Can establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

  1. 1The improvements were real and measurable, but it's not yet clear if they prevent blindness or just temporarily help vision.
  2. 2People who took the vitamins had higher eye pigment levels and saw better on eye charts after 12 months; doubling the dose didn't help more.

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data

Publication

Journal

Graefe's Archive for Clinical and Experimental Ophthalmology

Year

2013

Authors

J. Dawczynski, S. Jentsch, D. Schweitzer, M. Hammer, G. Lang, J. Strobel

106 citations
Analysis v5

Related Content

Claims (6)

Assertion

Taking a specific combination of lutein, zeaxanthin, DHA, EPA, and antioxidants daily for one year increases the density of protective pigment in the macula of people with non-exudative age-related macular degeneration. Doubling the dose does not increase this pigment further.

Causal
Read analysis
Assertion

Taking lutein, zeaxanthin, omega-3 fatty acids, and antioxidants together for 12 months increases the density of protective pigment in the macula and improves sharpness of vision in people with non-exudative age-related macular degeneration.

Causal
Read analysis
Assertion

Taking a daily supplement containing lutein, zeaxanthin, omega-3-LCPUFAs, and antioxidants for one year leads to measurable improvement in sharpness of vision in people with non-exudative age-related macular degeneration compared to taking a placebo.

Causal
Read analysis
Assertion

In people with non-exudative age-related macular degeneration who do not take supplements, the density of macular pigment decreases over 12 months. Daily nutrient intake is associated with a reduction in this decline.

Causal
Read analysis
Assertion

Taking lutein and zeaxanthin supplements at the studied dose leads to a maximum level of pigment in the macula; doubling the dose does not increase this pigment further.

Mechanistic
Read analysis
Assertion

Lutein and zeaxanthin build up in the central part of the retina and absorb blue light, which reduces damage to light-sensitive cells.

Mechanistic
Read analysis
Fit Body Science verdict — we translate health studies into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.